14 2010
Aker BioMarine, Lipogen Come Together To Develop Phospholipids Formula
Aker BioMarine, an integrated biotechnology company positioned to create value from krill harvesting and processing and Lipogen, a producer of the functional cognitive ingredient phosphatidylserine (PS), have joined forces to develop a phospholipids formula for cognitive health.
Aker BioMarine and Lipogen said that the target formula is a matrix of Lipogen PS phosphatidylserine produced from Aker BioMarine’s pure Superba Krill Oil. Reportedly, Phosphatidylserine (PS) and omega-3 fatty acids are both key components of the brain’s cell membranes. The new ingredient could either be applied together with multivitamins or as a single ingredient targeting brain health.
04 2010
Valensa International Recognized by Frost & Sullivan for Promoting Astaxanthin as an Eye Health Ingredient
Based on its recent analysis of the eye health astaxanthin market, Frost & Sullivan recognizes Valensa International with the 2009 North American Frost & Sullivan Award for Customer Value Enhancement. Valensa has expanded the market for astaxanthin by positioning its Zanthin® Natural Astaxanthin product as an eye health ingredient and not just an anti-oxidant for general well-being. It holds the Tso Patent, which allows it to promote the use of astaxanthin for eye health support and also as an ideal combination ingredient with lutein and zeaxanthin in eye health supplements. It also offers blend formulations of astaxanthin with AREDS2-backed Omega-3 fatty acids for eye health. Such a focused approach toward product application has helped it carve a niche for itself in the market.
23 2009
New Patent for Chemical-Free Krill Oil Extraction
Tharos, a Chile-based consultancy firm, has developed a new patent for krill oil extraction.
The chemical-free process relates to a processing layout for obtaining krill oil with DHA and EPA in the phospholipids fraction, with astaxanthin and neutral lipids, used for human health applications, and a byproduct of the process being a low fat content krill meal.
13 2009
Florida-based Valensa International has signed licensing agreements for its astaxanthin
Valensa’s deal comes at the same time it has joined with krill omega-3 specialist, Neptune Technologies and Bioressources to develop astaxanthin-omega-3 combinations.
Valensa says its patent-protected process (University of Illinois; US 5,527,533) can be used by New York-based FutureBiotics; North Dakota-based Swanson Health Products and Arizona-based Life Extension Vitamins in eye health supplements.
The patent is relevant for light-induced retinal damage, age-related macular degeneration, photoreceptor cell retinal damage and damage to neurons of inner retinal layers and produces an ingredient with a four-year shelf life, Valensa said.
28 2009
Cyanotech Announces 5 New Condition-Specific Formulas with Astaxanthin
Cyanotech’s Medical Director Robert Corish, MD has now formulated five condition-specific recipes featuring BioAstin® Natural Astaxanthin as the “star” of each. There are many areas of medical research on Astaxanthin, which led Dr. Corish to combine BioAstin with the best, industry-leading nutrients for each condition in efficacious dosages.
BioAstin’s benefits derive from its superior antioxidant activity and from its ability to support and maintain natural inflammatory response, enhancing skin, muscle and joint health. Cyanotech produces these products from microalgae grown at its 90-acre facility in Hawaii using patented and proprietary technology and distributes them to nutritional supplement, nutraceutical and cosmeceutical makers and marketers in more than 40 countries worldwide.
12 2009
BioAstin Natural Astaxanthin Reduces CRP Levels by over 20% in Human Clinical Trial
Recent company news reports that BioAstin® Natural Astaxanthin reduced C-reactive protein in a double blind, placebo controlled human clinical trial. The treatment group’s average CRP level went down an impressive 20.7% in just 8 weeks when taking BioAstin. Analysis of the results showed that they were statistically significant.
C-reactive protein is a key measurement of systemic or “silent” inflammation. “Silent” inflammation is inflammation that is present at low levels in the body for an extended period of time. Continued exposure to silent inflammation is theorized to be a root cause of a multitude of life threatening diseases. The American Heart Association has suggested that testing CRP levels in the blood may be a new measurement to assess cardiovascular disease risk. The independent researcher who completed this study said, “Other research suggests that systemic or silent inflammation may be implicated in many other life threatening diseases such as cancer, heart disease, stroke, diabetes and Alzheimer’s among others.”
RSS Feed 
Search
News Archive
Categories
Host
 |
Partners
 |
Sponsors
 |  |
Latest News
- Researchers worry that damage to the oceans could mean some species — and whatever chemicals they produce — will be lost before they’re found
- Neptune Technologies & Bioressources profits rise on krill oil success
- Shellfish Waste May Give Us “Vanishing Plastic”
- Solazyme Delivers 100% Algal-Derived Renewable Jet Fuel to U.S. Navy
- MDPI Publishes New Marine Drugs Issue: Volume 8, Issue 6
Recent Comments
- Константин on Aquapharm completes £4.2 million investment
- Арсений on MOU signed between Universiti Sains Malaysia (USM) and the Rheinische-Friedrich-Wilhelms University in Bonn, Germany, On Marine Biotech Development
- Валентин on Blue Bio Open Innovation (BBOI): Norway and Sweden Collaborate on Joint Marine Biotech Development
- Коля on MOU signed between Universiti Sains Malaysia (USM) and the Rheinische-Friedrich-Wilhelms University in Bonn, Germany, On Marine Biotech Development
- Olha on GRC hosts Marine Natural Products conference in California, Feb 2010
Share Aquapreneur
